

State of the Art Lecture: Chest Pain in the Emergency Department

ACCA Masterclass 2017

Professor Nicholas L Mills


Consultant Cardiologist

Butler BHF Senior Clinical Research Fellow

Royal Infirmary of Edinburgh

 @highSTEACS @troponinpapers

WE
ARE THE
ESC



Disclosures

- Funding:** High-STEACS clinical trial (PI) NCT01852123
British Heart Foundation Special Project Grant (SP/12/10/29922)
Abbott Diagnostics (reagent only)
- Sponsors:** University of Edinburgh
NHS Lothian
- Interests:** Consultancy and speaker fees (Roche, Abbott Diagnostics, Beckman & Coulter, Singulex, GlaxoSmithKline, Sanofi-Aventis); Research grants (Abbott Diagnostics)
- NICE Diagnostics Advisory Committee,
Scottish Inter-Collegiate Guideline Network

Universal definition of myocardial infarction




SYMPTOMS

ECG

BIOMARKERS

“A rise and/or fall of cardiac troponin with at least one value above the **99th percentile** upper reference limit (URL) from a healthy reference population”

Universal definition of myocardial infarction




23 countries across high and low to middle income countries (1,902 hospitals)


North America 400; Europe 402; South America 400; Asia Pacific 400; Middle east 239;
Africa 161

www.escardio.org/ACCA

Anand et al. 2016 (unpublished)




High-sensitivity cardiac troponin assays



- Greater analytical precision at very low concentrations (10-100 fold)
- Quantification of cardiac troponin concentrations in the majority of healthy persons
- **Permit development of accelerated diagnostic pathways**


Cardiac troponin concentrations within the reference range



n = 2,092

Cardiac troponin concentrations in normal reference range associated with risk


Chest pain attendances in the Emergency Department




Can we rule out myocardial infarction safely in the Emergency Department?

Royal Botanical Gardens, Edinburgh, Scotland

Rapid rule out in the Emergency Department




Rapid rule out pathways for myocardial infarction



ADP = accelerated diagnostic pathway;
cTn = cardiac troponin; hs = high-sensitivity

Accelerated Diagnostic protocol to Assess Patients with chest Pain symptoms using contemporary Troponins (ADAPT)



TIMI Score = 0

AND


No ischemia on ECG

AND

Troponin <99th centile at 0 and 2 hrs






20% identified as low risk with MACE rate of 1:400 at 30 days (NPV 99.7%)

Patients with negative findings for each component of ADAPT who had MACE during up to 30-days









Risk scores in the era of contemporary troponin testing








HEART Score

-  HISTORY
2 = Typical
1 = Atypical
-  ECG
2 = ST depression
1 = T-wave inversion
-  AGE
2 = ≥ 65
1 = $\geq 45 < 65$
-  RISK FACTORS
2 = 2 or more
1 = 1 or more
-  TROPONIN
2 = ≥ 3 x upper limit
1 = 1 - 3 x upper limit

GRACE Score


-  AGE (Years)
-  HEART RATE (bpm)
-  SYSTOLIC BP
-  CREATININE
-  CARDIAC ARREST
-  ST CHANGES ON ECG
-  ELEVATED TROPONIN
-  KILLIP CLASS

TIMI Score

-  AGE
1 = ≥ 65
-  RISK FACTORS
1 = 3 or more
-  CORONARY DISEASE
1 = Known stenosis
-  ASPIRIN USE
1 = Within 7 days
-  SEVERE ANGINA
1 = x 2 in 24 hours
-  ST CHANGES ON ECG
1 = ≥ 0.5 mm
-  TROPONIN
1 = >99 th centile

High-sensitivity cardiac troponin at 0 and 3 hours (European Society of Cardiology)

0 h
3 h



Upper limit of normal (ULN) = 99th centile

Retrospective validation of the ESC 0 and 3 hour pathway

Abbott ARCHITECT high-sensitivity troponin I assay >99th centile at presentation and 3 hours

		AMI	Not AMI	Sensitivity (%)	Specificity (%)	NPV (%)	PPV (%)
Brisbane ADAPT	Test positive	10	5	66.7	97.9	97.9	66.7
	Test negative	5	231	(38.3 to 88.2)	(95.1 to 99.3)	(95.1 to 99.3)	(38.4 to 88.2)
Christchurch ADAPT	Test positive	47	7	60.3	97.9	91.3	87.0
	Test negative	31	324	(48.5 to 71.2)	(95.7 to 99.1)	(87.8 to 93.9)	(75.1 to 94.6)
Christchurch ADAPT-ADP	Test positive	21	1	75.0	99.5	96.7	95.5
	Test negative	7	208	(55.1 to 89.3)	(97.4 to 100)	(93.4 to 98.7)	(77.2 to 99.9)
Christchurch EDACS	Test positive	6	1	75.0	98.9	97.8	85.7
	Test negative	2	91	(34.9 to 96.8)	(94.1 to 100)	(92.4 to 99.7)	(42.1 to 99.6)

Case 386

0 h


3 h



63 year old women with left sided chest pain 2 hours prior to arrival in the Emergency Department. Cigarette smoker with a family history of premature coronary artery disease. Examination normal. Initial 12-lead electrocardiogram was unremarkable

hs-cTnI concentrations were 10, 16 and 187 ng/L at presentation, and at 3 and 12 hours

Limitations of the 99th centile in 0 and 3 hour pathways



Age	Sex	0 hrs	3 hrs	Peak	Pain onset
82	F	11	15	26	150 mins
63	F	10	16	167	150 mins
74	M	5	8	57	180 mins
62	M	27	32	43	150 mins
87	M	5	16	691	150 mins
73	M	26	29	41	-
61	M	12	30	51	180 mins
75	M	23	25	39	150 mins

Age	Sex	0 hrs	3 hrs	Peak	Pain onset
58	M	26	33	46	180 mins
66	M	12	31	202	270 mins
60	M	2	6	2932	120 mins
56	M	8	14	307	-
77	M	21	26	56	270 mins
66	M	22	25	36	-
84	M	17	16	53	-
60	M	14	14	170	270 mins

n=330

hs-cTnI at presentation and at 3 hours missed 16/330 of patients with myocardial infarction identified at 12 hours

SHOULD WE USE DIFFERENT THRESHOLDS TO RULE IN AND RULE OUT MI?

Botanical Building, Balboa Park, San Diego, California

Ruling out with high-sensitivity cardiac troponin T using the limit of detection (LOD) at presentation

0 h


High-sensitivity cardiac troponin T < LOD (5 ng/L) at 0 h rules out myocardial infarction in 20-44% of patients with an NPV > 98.6%

Cohort	Year	n	FN	TN	NPV	Proportion
Manchester (1)	2011	703	0	130	100.0%	27%
APACE (2)	2013	2,072	8	542	98.6%	26%
Manchester (3)	2015	463	1	95	99.0%	20%
France (4)	2016	413	1	176	99.5%	43%
TRAPID-AMI (5)	2016	1,283	4	556	99.3%	44%

(1) Body et al JACC. 2011;54:1332; (2) Rubini Gimenez et al. Int J Cardiol. 2013;168:3896-901; (3) Body et al. Clin Chem. 2015;61:983-9. (4) Chenevier-Gobeaux et al. Clin Biochem. 2016;49:1113-1117. (5) Body et al. Acad Emerg Med. 2016;23:1004-13.

Enhanced precision with high-sensitivity cardiac troponin I

Abbott ARCHITECT high-sensitivity cardiac troponin I (hs-cTnI) assay



Coefficient of variation 20% ~ 2 ng/L

Optimal threshold to rule out at presentation with hs-cTnI

0 h

Aim: to define a threshold that identifies patients with suspected acute coronary syndrome at presentation as low risk of myocardial infarction for immediate discharge



Derivation: n=4,870 consecutive patients across hospitals in Scotland, UK




Validation: n=1,434 consecutive patients in Minneapolis, USA

Index myocardial infarction, subsequent myocardial infarction or cardiac death at 30 days

Optimal threshold to rule out at presentation with hs-cTnI

0 h




NPV is 99.6% (95% CI 99.3 to 99.8) at troponin concentrations <5 ng/L

n=4,870

Optimal threshold to rule out at presentation with hs-cTnI

0 h




n=4,870

Derivation cohort : 68% of women and 59% of men <5 ng/L on presentation

Performance of <5 ng/L threshold in key subgroups

0 h




Negative predictive value

n=4,870

One year outcomes in patients without myocardial infarction

0 h



n=4,870


Risk stratification of patients without myocardial infarction

HOW TO INTEGRATE RISK STRATIFICATION THRESHOLDS INTO THE PATHWAY

Scottish wildflowers, Edinburgh

High-STEACS pathway

Obtain presentation hs-TnI sample



*patients <2 hours from symptom onset require serial testing

Shah et al. Lancet 2016;387:2289-91

Validation of risk stratification thresholds

<5 ng/L at presentation

NPV [95%CI]

Carlton et al (3,155 patients)
JAMA Cardiology 2016

99.2% [98.8 - 99.5%]

<5 ng/L*

≥5 ng/L and
≤16 ng/L (women)
≤34 ng/L (men)

>16 ng/L (women)
>34 ng/L (men)

Boeddinghaus et al (2,828 patients)
Eur. Heart. J. 2016

99.1% [98.5 - 99.5%]

<3 ng/L at three hours

NPV [95%CI]

Internal Validation (310 patients)
Circulation 2017

98.8% [97.4-99.9%]

Change <3 ng/L
and
≤16 ng/L (women)
≤34 ng/L (men)


Change ≥3 ng/L
and
≤16 ng/L (women)
≤34 ng/L (men)

>16 ng/L (women)
>34 ng/L (men)

External Validation (2,533 patients)
Circulation 2017

99.9% [99.7-100%]

How do the High-STEACS and ESC pathways compare?




INDEX TYPE 1 MI

High-STEACS pathway

ESC 3 hour pathway

NPV 99.5% [99.0-99.9%]



NPV 97.9% [96.9-98.7%]



Rules out 74% at 3 hrs

Rules out 79% at 3 hrs

n=1,218



● High-STEACS


● ESC Pathway

Implementation of HighSTEACS pathway



EMERGENCY DEPARTMENT



HOSPITAL ADMISSION



* Retest at 3h if <2h from onset


High-Sensitivity cardiac Troponin at presentation to Rule out myocardial Infarction: (HiSTORIC) a stepped wedge cluster randomised trial

WE ARE THE ESC



Aim: to evaluate the efficacy and safety of implementation of High-STEACS pathway to rule out myocardial infarction in consecutive patients with suspected acute coronary syndrome





HighSTEACS

High-sensitivity Troponin in the Evaluation of Patients with Acute Coronary Syndrome


This pathway is for patients with chest pain and suspected acute myocardial infarction evaluated using the Abbott high-sensitivity cardiac troponin I assay

BETA TESTING VERSION


This is a beta version of the High-STEACS web app, which is undergoing testing before its official release. The High-STEACS pathway has been developed and validated as part of a prospective clinical trial. The current version of this app is for educational use and testing, but has not been approved to guide clinical decisions (see [Terms and Conditions](#)).

[Log Case](#) [Try Pathway](#)

Log In Required
Please refer to [Privacy Policy](#) for details of data use and cookies





Rapid rule out pathways for myocardial infarction



ADP = accelerated diagnostic pathway;
cTn = cardiac troponin; hs = high-sensitivity



Development of a one hour pathway for myocardial infarction



Rubini Gimenez et al. Am J Med. 2015; 128, 861-870

High-sensitivity cardiac troponin at 0 and 1 hours (European Society of Cardiology)

WE
ARE THE
ESC



Mueller C et al. Ann Emerg. Med. 2016;68:76-87;
Eur Heart J. 2016;37:267-315.

High-sensitivity cardiac troponin at 0 and 1 hours (European Society of Cardiology)






WE
ARE THE
ESC

0 h
1 h







		Hs-cTnT algorithm		Hs-cTnI algorithm	
2x2		AMI	Not AMI	AMI	Not AMI
Algorithm did not rule-out		233	564	237	780
Algorithm ruled-out		7	1419	3	1202
Sensitivity (95%CI)		97.1 (94.0 to 98.8)		98.8 (96.4 to 99.7)	
NPV (95%CI)		99.5 (99.0 to 99.8)		99.8 (99.3 to 99.9)	
Proportion Rule-Out (%)		64.2		54.2	

Is there a role for 'scores' if hs-cTnI is used to risk stratify?




HEART Score

-
-  HISTORY
2 = Typical
1 = Atypical
-  ECG
2 = ST depression
1 = T-wave inversion
-  AGE
2 = ≥ 65
1 = $\geq 45 < 65$
-  RISK FACTORS
2 = 2 or more
1 = 1 or more
-  TROPONIN
2 = ≥ 3 x upper limit
1 = 1 - 3 x upper limit


GRACE Score

-
-  AGE (Years)
-  HEART RATE (bpm)
-  SYSTOLIC BP
-  CREATININE
-  CARDIAC ARREST
-  ST CHANGES ON ECG
-  ELEVATED TROPONIN
-  KILLIP CLASS


TIMI Score

-
-  AGE
1 = ≥ 65
-  RISK FACTORS
1 = 3 or more
-  CORONARY DISEASE
1 = Known stenosis
-  ASPIRIN USE
1 = Within 7 days
-  SEVERE ANGINA
1 = x 2 in 24 hours
-  ST CHANGES ON ECG
1 = ≥ 0.5 mm
-  TROPONIN
1 = >99 th centile

Is there a role for 'scores' if hs-cTnI is used to risk stratify?



High-sensitivity cardiac troponin at 0 and 3 hours (European Society of Cardiology)



IMPROVING PATIENT SELECTION FOR CARDIAC TROPONIN TESTING




*Charles Jenks' Cells of Life, Jupiter Artland,
Edinburgh, Scotland*

Universal definition of myocardial infarction

WE
ARE THE
ESC

- 1** **TYPE 1 MYOCARDIAL INFARCTION**
Spontaneous myocardial infarction related to ischaemia due to a primary coronary event such as plaque erosion and/or rupture, fissuring, or dissection
- 2** **TYPE 2 MYOCARDIAL INFARCTION**
Myocardial infarction secondary to ischaemia due to either increased oxygen demand or decreased supply
- 3** **TYPE 3 MYOCARDIAL INFARCTION**
Sudden unexpected cardiac death often with symptoms suggestive of myocardial ischaemia
- 4** **TYPE 4 MYOCARDIAL INFARCTION**
Myocardial infarction associated with percutaneous coronary intervention (4a) or stent thrombosis (4b)
- 5** **TYPE 5 MYOCARDIAL INFARCTION**
Myocardial infarction associated with cardiac surgery
- Injury** **MYOCARDIAL INJURY**
Multifactorial aetiology; acute or chronic based on change in cardiac troponin concentrations with serial testing



Vasospasm or endothelial dysfunction



Fixed atherosclerosis and supply-demand imbalance



Supply-demand imbalance alone



1


2

2

Injury



Type 2 myocardial infarction and myocardial injury is common



- 1
- 2
- Injury




Shah AS et al Am J Med. 2015;128:493-501.

n = 2,929



Variation in the approach to cardiac troponin testing: impact on the prevalence of type 1 myocardial infarction

WE
ARE THE
ESC



How does the approach to cardiac troponin testing effect performance?

Prospective cohort study across two independent consecutive patient cohorts presenting to the Emergency Department



Unselected testing
(n=1,054)




Selected testing
(n=5,815)

Primary outcome: diagnosis of type 1 myocardial infarction


How does the approach to cardiac troponin testing effect performance?

WE
ARE THE
ESC

Unselected testing



Selected testing



● >99th centile

How does the approach to cardiac troponin testing effect performance?



Unselected testing

Type 1 MI 2%
Type 2 MI 1%
Myocardial injury 11%

Selected testing


Type 1 MI 14%
Type 2 MI 4%
Myocardial injury 80%

Positive predictive value




Impact of troponin testing on diagnosis of type 1 myocardial infarction

WE
ARE THE
ESC




Impact of troponin testing on diagnosis of type 1 myocardial infarction

WE
ARE THE
ESC



How can we improve the positive predictive value of troponin testing?



Shah et al. 2016 (under review)

Conclusions and summary

- High-sensitivity cardiac troponin I assays are changing the way we risk assess and diagnose patients with suspected myocardial infarction
- Patients with very low cardiac troponin concentrations are at low risk and may not require hospital admission or further investigation
- Integration of risk stratification thresholds into early rule out pathways appears to improve safety and permits myocardial infarction to be ruled in or out by 3 hours in ~95% of patients
- The true safety and efficacy of these pathways needs to be confirmed in trials evaluating their implementation in clinical practice



Acknowledgments




British Heart Foundation Special Project Grant
(SP/12/10/29922) and Butler Senior Clinical Research
Fellowship (FS/16/04/32023)

Sex-differences in the 99th centile upper reference limit




Definitive normal range (DNR) study



Reference range of high-sensitivity cardiac troponin assays

Diagnosis of type 1 myocardial infarction



SENSITIVITY